Latest Pharma and Biotech News
Pharmaceutical
16 April 2026 In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033.
Today's issue
Refine search
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B (TLB), alongside a revolving credit facility. 17 April 2026
Pharmaceutical
Recently-launched US obesity company Kailera Therapeutics has announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. 17 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Pharmaceutical
US President Donald Trump has nominated Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC) after a long search for a replacement for Susan Monarez, who was sacked in August last year. 17 April 2026
Pharmaceutical
The European Investment Bank (EIB) Group, the European Commission and the International Finance Corporation (IFC) have announced support for Biovac’s development of Africa’s first end-to-end multi-vaccine manufacturing facility in South Africa, in a financing package aimed at strengthening regional health security and vaccine self-reliance. 17 April 2026
Pharmaceutical
Indian CDMO Piramal Pharma has entered a strategic collaboration with Japan’s Ajinomoto Bio-Pharma Services to support antibody-drug conjugate (ADC) development and manufacturing. 17 April 2026
Pharmaceutical
US pharma major Eli Lilly has announced positive top-line results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. 17 April 2026
Pharmaceutical
California-based liver and viral disease specialist Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection, the company announced yesterday. 17 April 2026
Pharmaceutical
Ryght AI, a provider of real-time generative AI solutions for the clinical research industry, has announced the launch of RyghtSites.com.
The free, publicly accessible tool allows pharmaceutical companies and Contract Research Organizations (CROs) to instantly search, rank, and download lists of the world's best clinical research sites for your search. 17 April 2026
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (ICER), in collaboration with Verdant Research, has published a new white paper that examines the evolution – and perception – of the Food and Drug Administration (FDA) accelerated approval pathway. 16 April 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo says it has agreed to transfer all of its shares in Daiichi Sankyo Healthcare (DSHC), a consolidated subsidiary of the company, to Suntory Holdings and today entered into a stock transfer agreement with Suntory HD. 16 April 2026
Pharmaceutical
USA-based SQ Innovation has struck a long-term supply agreement with Italian active pharmaceutical ingredient (API) specialist FIS to secure pharmaceutical-grade furosemide for its marketed product Lasix ONYU and future pipeline assets. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Pharmaceutical
The US Food and Drug Administration will ask outside advisers in July whether some peptide substances should be allowed on the 503A Bulks List, a step that could reopen debate over compounded products now popular in wellness and performance circles. 16 April 2026
Pharmaceutical
German drugmaker Bayer has highlighted publication of full results from its Phase III OCEANIC-STROKE trial in the New England Journal of Medicine, adding weight to its case for the investigational anticoagulant asundexian. 16 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Pharmaceutical
New research from researchers at the University of Florida, University of Maryland and Yale School of Public Health has found that if measles, mumps and rubella (MMR) immunization rates continue to fall, even by just a percentage point, measles could re-establish itself as an endemic disease in the USA within years. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced that Health Canada has approved Neffy 2mg adrenaline (epinephrine) nasal spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adult and paediatric patients (≥30 kg). 15 April 2026
All news
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B (TLB), alongside a revolving credit facility. 17 April 2026
Pharmaceutical
Recently-launched US obesity company Kailera Therapeutics has announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. 17 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Pharmaceutical
US President Donald Trump has nominated Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC) after a long search for a replacement for Susan Monarez, who was sacked in August last year. 17 April 2026
Pharmaceutical
The European Investment Bank (EIB) Group, the European Commission and the International Finance Corporation (IFC) have announced support for Biovac’s development of Africa’s first end-to-end multi-vaccine manufacturing facility in South Africa, in a financing package aimed at strengthening regional health security and vaccine self-reliance. 17 April 2026
Pharmaceutical
Indian CDMO Piramal Pharma has entered a strategic collaboration with Japan’s Ajinomoto Bio-Pharma Services to support antibody-drug conjugate (ADC) development and manufacturing. 17 April 2026
Pharmaceutical
US pharma major Eli Lilly has announced positive top-line results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. 17 April 2026
Pharmaceutical
California-based liver and viral disease specialist Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection, the company announced yesterday. 17 April 2026
Pharmaceutical
Ryght AI, a provider of real-time generative AI solutions for the clinical research industry, has announced the launch of RyghtSites.com.
The free, publicly accessible tool allows pharmaceutical companies and Contract Research Organizations (CROs) to instantly search, rank, and download lists of the world's best clinical research sites for your search. 17 April 2026
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (ICER), in collaboration with Verdant Research, has published a new white paper that examines the evolution – and perception – of the Food and Drug Administration (FDA) accelerated approval pathway. 16 April 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo says it has agreed to transfer all of its shares in Daiichi Sankyo Healthcare (DSHC), a consolidated subsidiary of the company, to Suntory Holdings and today entered into a stock transfer agreement with Suntory HD. 16 April 2026
Pharmaceutical
USA-based SQ Innovation has struck a long-term supply agreement with Italian active pharmaceutical ingredient (API) specialist FIS to secure pharmaceutical-grade furosemide for its marketed product Lasix ONYU and future pipeline assets. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Pharmaceutical
The US Food and Drug Administration will ask outside advisers in July whether some peptide substances should be allowed on the 503A Bulks List, a step that could reopen debate over compounded products now popular in wellness and performance circles. 16 April 2026
Pharmaceutical
German drugmaker Bayer has highlighted publication of full results from its Phase III OCEANIC-STROKE trial in the New England Journal of Medicine, adding weight to its case for the investigational anticoagulant asundexian. 16 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Pharmaceutical
New research from researchers at the University of Florida, University of Maryland and Yale School of Public Health has found that if measles, mumps and rubella (MMR) immunization rates continue to fall, even by just a percentage point, measles could re-establish itself as an endemic disease in the USA within years. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced that Health Canada has approved Neffy 2mg adrenaline (epinephrine) nasal spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adult and paediatric patients (≥30 kg). 15 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze